xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

396

International consensus statement on rhinosinusitis

(Continues)

TABLE IX-26 Evidence for CRSsNP management with topical nasal corticosteroids (standard delivery with sprays) Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Chong 1073 2016 1 Meta-analysis (n = 269 CRSsNP) INCS Placebo/No treatment HRQL Disease severity Slight improvement with steroid for general health subscale, no effect on other HRQL or disease severity for CRSsNP. Snidvongs 1067 2011 1 Meta-analysis (n = 590) INCS Placebo (or antibiotics) Symptom scores QoL Adverse events INCS improved symptom scores. No change in QoL. No adverse events. Kalish 1061 2009 1 Systematic review (n = 657) INCS Placebo (or antibiotics) Overall response to treatment Symptoms Insufficient evidence to demonstrate a clear benefit with INCS. Possible improvement in symptom scores. Mosges 1070 2011 2 DBRCT (n = 53) Mometasone furoate 200 μ gBID Placebo Total symptom score Patient evaluation treatment response Endoscopy score Adverse events No difference in total symptom score between groups. Significant improvement in endoscopic score. Zeng 1072 2011 2 RCT– single-blinded, treatment comparison study (n = 43) Mometasone furoate 200 μ gdaily Clarithromycin 250 mg daily Symptom score Endoscopy score Overall symptom burden score Improvement in symptom scores and endoscopy scores in both groups.

No significant difference in total endoscopic score or

symptom scores between groups.

Endoscopic score

Symptom scores

Adverse events

Mometasone furoate 200 μ gBID Placebo

Jorissen 1068 2009 2 DBRCT (n = 99) 6 month course, starting 2 weeks post-surgery